AZD 9056
Alternative Names: AZD9056Latest Information Update: 05 Nov 2023
At a glance
- Originator AstraZeneca
- Class Antirheumatics
- Mechanism of Action Purinergic P2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Inflammatory bowel diseases; Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 18 Aug 2009 Discontinued - Phase-II for Rheumatoid arthritis in Argentina (PO)
- 18 Aug 2009 Discontinued - Phase-II for Rheumatoid arthritis in Australia (PO)
- 18 Aug 2009 Discontinued - Phase-II for Rheumatoid arthritis in European Union (PO)